Chinese and foreign pharmaceutical companies have joined forces to become the trend.

"Pharmaceutical Network Industry Dynamics" Recently, Ipson China ("Ipson") and Shanghai Pharmaceutical Holdings Co., Ltd. ("Pharmaceutical Holdings") held a signing ceremony at the headquarters of Shanghai Pharmaceutical Holdings.
Jialin, general manager of Ipsos China, and Li Yongzhong, general manager of Shanghai Pharmaceutical Holdings Co., Ltd., signed a cooperation agreement on behalf of Fusong (Polyglycol 4000 Scatter) in completely channels.
that the cooperation is aimed at continuing to promote the application of Fusong (polyglycol 4000 scattered) in the field and better meet the needs of patients.
this time, Shanghai Pharmaceutical Holdings will focus its own advantages of resources, through the network system throughout the country's 24 provinces, to further improve the access of patients.
ipso and Ipsum Group hopes to better serve patients through this partnership, while expanding its diversified business development model and accelerating the strategic layout of the multi-health sector.
fact, in recent years, with the changing pharmaceutical industry, the market is more open, Chinese and foreign pharmaceutical companies frequently strong joint efforts to jointly develop the domestic and international pharmaceutical market trend has become more and more obvious.
recently, on August 17th, Bayer announced a strategic partnership with Huali Pharmaceuticals, an innovative drug research and development company, to reach a commercial cooperation agreement in China on the new diabetes treatment drug dorzagliatin.
that the agreement will give Bayer a leading role in diabetes management in China and the innovative capabilities of Hua-Li Pharmaceuticals to provide new treatment options for people with diabetes in China.
July 15, Novartic and Noud and China Resources Pharmaceuticals also announced that, based on the earlier letter of intent signed by the two sides, No. and Nord and China Resources Pharmaceuticals' China Resources 39 Pharmaceutical Co., Ltd. will jointly promote the recombinant human growth hormone injection Noze ® Chinese mainland through a contract sales model.
the partnership, which will take effect on August 1, 2020, aims to further improve ®'s access in China and benefit more Chinese patients.
November 1, 2019, Baiji Shenzhou, an innovative pharmaceutical company listed in both U.S. and Hong Kong stocks, announced a strategic global cancer partnership with U.S. pharmaceutical giant Amjin.
, Amson will buy a 20.5 per cent stake in Baiji Shenzhou for about $2.7bn in cash, or $174.85 a share for ads.
as a whole, the model of international cooperation among pharmaceutical companies is gradually being accepted by the market.
fact, the increasing cooperation between Chinese and foreign pharmaceutical companies is caused by many factors.
At present, China's pharmaceutical market position in the global market can not be ignored, coupled with china's drug review and approval speed up, the future foreign giants want to get a piece of the Chinese market, the trend of cooperation with Chinese enterprises will be further strengthened, the number of cases of Sino-foreign strong joint will be more and more.
But industry insiders also point out that in the future, only companies with strong research and development capabilities, especially those focused on a disease area, as well as those with drug reporting capabilities and excellent drug commercialization capabilities, will become the focus of cooperation between multinational pharmaceutical companies.
.